Impax Laboratories, Inc. announced earlier this week that EMVERM (mebendazole) 100 mg chewable tablets are now available for healthcare providers to prescribe to patients in the United States.
![Pinworm egg/CDC](https://outbreaknewstoday.com/wp-content/uploads/2016/01/14617_lores.jpg)
EMVERM is indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura(whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale(common hookworm), Necator americanus (American hookworm) in single or mixed infections.
Pinworm is a highly contagious parasite that infects approximately 40 million people in the United States each year. Pinworm infection is three times more common than head lice. EMVERM offers a 95% cure rate in a single 100 mg dose. EMVERM is not for persons who have shown hypersensitivity to the drug.
For additional information, see the Impax Laboratories Press Release
Related:
- UTI treatment: FDA grants Fast Track Designation to investigational antibiotic, CARBAVANCE
- CLL treatment, Venclexta receives FDA approval
- Genital herpes treatment: Genocea Biosciences announce data from Phase II trials
![Impax Laboratories Launches New Logo (PRNewsFoto/Impax Laboratories, Inc.)](https://outbreaknewstoday.com/wp-content/uploads/2016/04/180590LOGO.jpg)
2 thoughts on “Chewable parasite drug, EMVERM, now available for treatment pinworm, others”